Recruiting studies: Immune Mediated Thrombotic Thrombocytopenic Purpura

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417 Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07513948 Association of TNFAIP3 With Immune-mediated TTP
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT06928233 RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072247 Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune
NA · 30 location(s) · University Hospital, Rouen · NCT06291025 A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Phase 2 · 1 location(s) · University of Minnesota · NCT06831058

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.